KORU Medical Systems demonstrates a strong core business model based on recurring revenue from a stable chronic patient base and differentiated infusion technology. Its international expansion and pipeline diversification into new drug labels and oncology clinics provide credible growth optionaliti…
KORU Medical Systems (KRMD) Q1 2025: International Growth Surges 36%, Raising Full-Year Revenue Outlook
KORU Medical delivered robust 18% revenue growth in Q1 led by international expansion and core business strength. The company raised full-year revenue guidance on sustained market share gains and pipeline progress. Strategic diversification into new drug labels and oncology infusion clinics positions KORU for accelerated growth beyond its SCIG foundation.
Summary
- International Expansion Momentum: Rapid geographic growth and tender wins fuel outsized revenue gains.
- Pipeline Diversification: New drug label submissions and oncology pilot programs broaden market opportunity.
- Operational Discipline: Margin improvement and positive cash flow underpin raised guidance and financial health.
Business Overview
KORU Medical Systems develops and commercializes large volume subcutaneous infusion solutions primarily for immunoglobulin (SCIG) therapies. Its revenue is concentrated in two core segments: domestic and international SCIG infusion systems and consumables, which represent recurring revenue from chronic patients, and a smaller pharma services and clinical trials segment. The company is expanding into new drug categories and infusion clinic markets to diversify beyond its legacy SCIG base.
Performance Analysis
KORU Medical posted $9.6 million in Q1 2025 revenues, an 18% increase over Q1 2024, driven by a 21% growth in the core business. Domestic core revenues rose 16%, supported by new patient starts and market share gains, outpacing the approximately 10% SCIG market growth. International core revenues surged 36% to $2.4 million, reflecting geographic expansion, a key prefilled syringe tender win, and distributor stocking to support new markets. The pharma services segment declined 39%, consistent with its non-recurring nature and timing shifts in clinical trial activity.
Gross margin improved 50 basis points to 62.8%, reflecting favorable product mix and operational efficiencies that offset tariff-related cost pressures. Operating expenses increased modestly by 3.2%, primarily due to temporary staffing and legal fees, while net loss narrowed by 36% to $1.2 million. Adjusted EBITDA loss improved to $0.2 million from $0.9 million a year ago, signaling progress toward profitability. Cash usage was $0.8 million, with a strong $8.7 million ending cash balance supporting ongoing investments.
- Core Business Resilience: Recurring revenue from 45,000 chronic SCIG patients and expanding market share drive steady growth.
- International Growth Engine: Expansion into new geographies and tender wins underpin outsized 36% revenue increase.
- Margin Expansion Amid Inflation: Operational improvements and product mix gains offset tariff impacts within gross margin guidance.
Overall, KORU demonstrated balanced growth and improved financial health, positioning it to capitalize on expanding market opportunities and pipeline catalysts.
Executive Commentary
"We are off to a strong start this year, with over 20% growth in our core business driven by new patient starts and continued market share gains both domestically and internationally, all contributing to the expansion of our recurring revenue base."
Linda Tharby, President and CEO
"We are raising full year 2025 revenue guidance to $38.5 to $39.5 million, representing 15% to 17% growth, driven by sustained global SCIG market growth, our international expansion, and the addition of new drug collaborations."
Tom Adams, Chief Financial Officer
Strategic Positioning
1. Accelerating International Expansion
KORU is capitalizing on a $60 million international SCIG total addressable market (TAM), currently holding about 10% share with ambitions to reach 30% to 40%. Growth is fueled by new distributor relationships in the Middle East, North Africa, and Europe, and a pivotal prefilled syringe tender win in a historically electronic pump-dominated EU market. The company expects continued 30% international growth in 2025, leveraging IG pharma partnerships and new pump technology launches to deepen penetration.
2. Diversifying Through New Drugs on Label
The company is expanding beyond its SCIG legacy by pursuing 17 active collaborations for new drug indications and device clearances. Notably, KORU plans to submit two commercialized drugs—iron chelation and antibiotics—for FDA 510(k) clearance independently, driven by demand from specialty pharmacy partners. These additions could add approximately $0.5 million in revenue in 2026 and reflect a scalable, low-capital approach to broadening the product portfolio.
3. Entering Oncology Infusion Clinics
KORU is piloting its Freedom Infusion System in five major US oncology infusion centers, targeting workflow efficiency gains and reimbursement advantages over manual infusion methods. Early feedback suggests potential for increased patient throughput and higher reimbursement rates, positioning the company to unlock a new revenue stream. The company plans to publish pilot data to support broader adoption.
4. Operational Excellence and Margin Management
Despite inflationary pressures and tariffs, KORU improved gross margin by 50 basis points through product mix optimization and manufacturing efficiencies. The company maintains a gross margin guidance of 61% to 63% for 2025, inclusive of tariff impacts. Investments in next-generation consumable production lines are underway to support future margin expansion and competitive positioning.
5. Sustained Growth and Cash Flow Focus
Management targets sustained 20%+ revenue growth driven by core market share gains, pipeline commercialization, and international expansion. Positive cash flow from operations is expected for 2025, supported by disciplined expense management and capital investments focused on scalable growth initiatives.
Key Considerations
KORU’s Q1 results reinforce a multi-pronged growth strategy balancing core SCIG market leadership with diversification into new drug labels and infusion clinics. Key considerations for investors include:
- Recurring Revenue Stability: Approximately 75% of revenues derive from chronic SCIG patients, providing a resilient and growing base.
- International Market Volatility: Distributor stocking creates quarterly revenue timing variability but supports long-term expansion.
- Regulatory and Commercial Execution: Timely FDA 510(k) clearances for new drugs and successful pilot outcomes in oncology clinics are critical inflection points.
- Tariff and Supply Chain Risks: While tariff impacts are modest and managed, ongoing geopolitical risks require vigilance.
- Capital Allocation Discipline: Investments focus on next-generation products and scalable pipeline opportunities with rapid payback profiles.
Risks
KORU faces risks including regulatory clearance delays, slower-than-expected adoption of new drug labels, and competitive pressures from electronic pump systems. International expansion involves execution risks related to distributor relationships and market acceptance. Tariff uncertainties and inflationary cost pressures could impact margins despite current mitigation efforts.
Forward Outlook
For Q2 2025, KORU expects continued international growth around 30%, with some sequential variability due to prior distributor stocking. Domestic growth is anticipated to outpace the approximately 10% SCIG market expansion. The novel therapies pipeline is expected to contribute between $2.5 million and $3 million in revenue.
- Full-year 2025 revenue guidance raised to $38.5 million to $39.5 million, representing 15% to 17% growth.
- Gross margin guidance reiterated at 61% to 63%, inclusive of tariff impacts.
- Positive cash flow from operations expected for the full year.
Management highlighted sustained SCIG market growth, new international market entries, and pipeline advancements as key drivers supporting the raised outlook.
Takeaways
KORU Medical’s Q1 performance signals a company successfully executing a dual strategy of deepening its SCIG core business while expanding into adjacent growth areas. The raised guidance reflects confidence in sustaining momentum despite macroeconomic challenges.
- Growth Engine Validated: International expansion and domestic market share gains underpin robust top-line growth and margin improvement.
- Pipeline as Growth Catalyst: New drug label submissions and oncology clinic pilots offer scalable revenue streams with low capital intensity.
- Operational Discipline Supports Financial Health: Margin expansion and reduced net loss demonstrate improving profitability trajectory, critical for long-term valuation.
Conclusion
KORU Medical’s first quarter results and strategic initiatives position the company well for sustained growth. The combination of core SCIG market strength, international expansion, and pipeline diversification provides a solid foundation to exceed raised 2025 guidance and drive shareholder value.
Industry Read-Through
KORU’s strong international growth and successful tender wins underscore the expanding global demand for subcutaneous infusion therapies, particularly in emerging markets. The company’s approach to adding new drug labels independently signals a broader industry trend toward platform versatility and closer integration with specialty pharmacies. Additionally, pilot programs targeting oncology infusion centers highlight the growing importance of workflow efficiency and reimbursement optimization in infusion therapy markets. Other medical device and pharma companies should monitor these developments as indicators of evolving competitive dynamics and growth opportunities in drug delivery and infusion systems.